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A Phase III Randomised Trial Of Chemo-Immunotherapy Comprising Gemcitabine 
And Capecitabine (GemCap) With Or Without Telomerase Peptide Vaccine GV1001 In 
Patients With Locally Advanced Or Metastatic Pancreatic Cancer: Final Results Of 
The TeloVacTrial. 
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SUMMARY 
Background.This study tested the survival efficacy in advanced pancreatic cancer of 
telomerase vaccination (GV1001) in combination with sequential or simultaneous 
chemotherapy. 
Methods.TeloVac was a three-arm, randomised phase III trial in locally advanced/metastatic 
pancreatic cancer and  is registered as an International Standard Randomised Controlled Trial 
(ISRCTN4382138). The primary end-point was to investigate the efficacy of GV1001 on 
length of survival when added concurrently or sequentially to the combination of gemcitabine 
and capecitabine (target=1110 patients; 2-sided α=0·025 for each comparison with control). 
Eligible patients were treatment naïve, aged >18 years, with locally advanced or metastatic 
pancreatic ductal adenocarcinoma, and performance status of 0-2. Chemotherapy comprised 
six cycles of gemcitabine (1000mg/m
2
30min intravenous infusion, days 1, 8, and 15) and 
capecitabine (830 mg/m
2 
orally twice daily for 21 days, repeated every 28 days). Sequential 
chemoimmunotherapycomprised two cycles of combination chemotherapy,then an 
intradermal lower abdominal injection of granulocyte-macrophage colony-stimulating factor 
(75μg), and GV1001 (0·56 mg) (days 1, 3, and 5, once on weeks2-4, and 6 monthly 
thereafter). Concurrent chemoimmunotherapycomprisedgiving GV1001 from the start of 
chemotherapy. Treatments were allocated with equal probability by means of computer-
generated random permuted blocks of sizes 3 and 6 in equal proportion. Analysis was by 
intention to treat. 
Findings.The final results show that the median overall survival times for the chemotherapy 
(n=358), sequential chemoimmunotherapy (n=350) and the concurrent chemoimmunotherapy 
(n=354) arms were 7.89 (95% CI: 7.07- 8.85), 6.94 (95% CI 6.35-7.6) and 8.36 (95% CI: 7.30 
-9.74) months respectively. The corresponding hazard ratios for the chemoimmunotherapy 
arms were 1.19 (98.25% CI: 0.97-1.48, p=0.047) and 1.05 (98.25% CI: 0.85-1.29, p=0.64), 
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with an overall log-rank χ22df= 4.3; P=0•11).  The corresponding median times to progression 
were 6.35 (95% CI: 4.77- 7.07), 4.54 (95% CI 4.34-4.61) and 6.58 (95% CI: 5.03 -7.27) 
months, with corresponding hazard ratios for the chemoimmunotherapy arms of 1.50 (98.25% 
CI: 1.26-1.78, p<0.001) and 1.0 (98.25% CI: 0.84-1.19, p=0.99) with an overall log-rank χ22df 
= 29·5; P<0•001).  Delayed type hypersensitivity was positive in 19 (12·3%) of 154 and 47 
(20·2%) of 233 patients with sequential and concurrent chemoimmunotherapyrespectively 
(P=0·053).  
The commonest grade 3/4 toxicities were neutropenia that occurred  in 68 (19 %), 58 (17 %) 
and 79 (22 %)  patients (Χ22df=3·76; p=0·15) in the chemotherapy, sequential 
chemoimmunotherapy and the concurrent chemoimmunotherapy arms respectively;  fatigue in 
27 (7%), 36 (10%) and 44 (12%) patents respectively (Χ22df=4·72; p=0·094); and pain in 34 
(9%), 39 (11%) and 42 (11%) patients respectively (Χ22df=1·09; p=0·58). 
Interpretation. Adding GV1001 vaccination to chemotherapy did not improve survival. 
Stopping chemotherapy after two cycles was associated with reduced time to progression and 
suggests that treatment until progression is the appropriate approach in pancreatic cancer. 
Vaccination to telomerase can elicit immune responses during chemotherapy but without 
clinical efficacy but could be overcome by newer strategies. 
Funding: Cancer Research UK and KAEL-GemVax. 
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INTRODUCTION 
The outcome of patients with advanced pancreatic cancer remains poor.
1
The median survival 
for those with metastatic disease is below 12 months even when treated with the most active 
chemotherapyregimens.
2,3
Radiotherapy appears to add little to the management of those with 
unresectable locally advanced disease.
4
Thus, more effective therapeutic strategies are 
required with immunotherapy being a  most promising approach.
5,6 
 
During repeated rounds of DNA replication the telomeric ends of DNA become progressively 
shortened and without a compensatory mechanism cells senesce and die.
7,8
Reactivation of 
telomerase is a crucial event in transformation and occurs in nearly all pancreatic 
cancers.
9
GV1001 is a  human telomerase reverse transcriptase catalytic subunit (hTERT) 
class II 16mer peptide vaccine .
7,8
A phase II trial of GV1001 in advanced pancreatic cancer 
showeda total immune response in 24 (63.2%) of 38 patients providing agreater median 
survival in immune responders of 216 days compared to 88 days for non-responders.
10 
Patients treated with the vaccine doses and  schedule applied in the current trial, had the 
highestimmune response (75%) .
10 
GV1001 vaccinationhas been shown to generate multiple 
CD4+ clones that recognised naturally processed hTERT generating fragments fitting into 
multiple class II molecules.  The clones also recognised T cell-depleted mononuclear cells 
from a patient with malignant ascites. Studies in other cancer patients have shown that 
GV1001 induces CD8+ cytotoxic T cells and can initiate epitope spreading.
10-13
 
 
 
Although cytotoxicsare generally regarded as immunosuppressive, certain chemotherapy 
regimens may potentiate the effect ofcancer vaccines.
14-19
Gemcitabine and 5-fluorouracil 
induce apoptosis of cancer cells leading to the release of antigens which can be taken up by 
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professional antigen presenting cells and cross-presented to prime cytotoxic T-
lymphocytes.
14,20
Ligation ofCD40 on antigen presenting cells withCD40L present on 
activated CD4+ cells determines the generation of cytotoxic T-lymphocytes.GV1001 
vaccination was expected to generate telomerase-specific T helper cells in order to activate 
multipleantigen presenting cells loaded with diverse antigens,to prime and activate cytotoxic 
T-lymphocytes with a broad repertoire.  Synergy between CD40 ligation and gemcitabine is 
maximal when gemcitabine is given prior to CD40 ligation.
21 
Chemotherapy delivered after 
immunotherapy can enhance the effect of immunotherapy by delivering a bolus of tumour 
antigens and immunostimulatory signals.
15
Thus pre-clinical studies had clearly shown 
synergy between gemcitabine and both CD40 agonism and vaccines in certain cancer models. 
14,15,21
 
 
 
The combination of gemcitabine and capecitabine (an orally active 5-fluorouracil pro-drug) is 
a standard of care with improved objective response and time to progression compared to 
gemcitabine montherapy.
22 
The design of the TeloVac study was based on  the clear clinical 
evidence of immunogenicity of GV1001 in patients with pancreatic cancer, the available pre-
clinical data demonstrating the synergy of gemcitabine with cancer vaccines and the other 
positive immunomodulatory effects of gemcitabine and fluoropyrimidines.  Thus the TeloVac 
study aimed to exploit the positive immunomodulatory effects of these agentsand tested the 
impact of combining GV1001 with granulocyte-macrophage colony-stimulating factor (GM-
CSF) as an adjuvant.
23
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METHODS 
Study Design and Participants 
TeloVac was a multicentre, three-arm, parallel group, open-label, phase III randomised 
controlled trial conducted at 51 United Kingdom sites. Eligible patients were treatment naïve, 
aged >18 years, with histologically or cytologically confirmed locally advanced or metastatic 
pancreatic ductal adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0-2 and adequate end organ function. Other specific inclusion criteria 
were locally advanced or metastatic disease precluding curative surgical resection or patients 
who have relapsed following previously resected pancreatic cancer; contrast enhanced 
computed tomography (CT ) scan  of the thorax, abdomen and pelvis within 28 days prior to 
commencing treatment; unidimensionally measurable disease on CT in accordance with the 
RECIST guidelines; platelet count ≥100 x 109/L, white blood cell count (WBC) ≥ 3 x 109/L 
and  neutrophil count ≥ 1.5 x 109/L at entry; serum bilirubin ≤ 35 μmol/L; calculated 
creatinine clearance over 50 ml/min (Cockcroft and Gualt); and  a life expectancy > 3 
months. Information on prior radical surgery and specific sites of metastatic disease was not 
collected. Previous adjuvant chemotherapy following resection was allowed if completed >12 
months previously. The estimated median (95% CI) survival of eligible patients was 7.1 (6.2, 
7.8) months.
22 
 
Patients were excluded if they had radiotherapy within the previous four weeks.  No other 
information on radiotherapy was collected as this was not used in the UK for locally 
advanced pancreatic cancer. Specific exclusion criteria were medical or psychiatric 
conditions compromising informed consent; intracerebral metastases or meningeal 
carcinomatosis; clinically significant serious disease or organ system disease not currently 
controlled on present therapy; uncontrolled angina pectoris; pregnancy or breast feeding; 
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previous chemotherapy for locally advanced and metastatic disease; radiotherapy within the 
last 4 weeks prior to start of study treatment; concurrent malignancies or invasive cancers 
diagnosed within the past 5 years except for adequately treated basal cell carcinoma of the 
skin, in situ carcinoma of the uterine cervix or resected pancreatic cancer; known 
malabsorption syndromes; hypersensitivity to any of the investigational products or patients 
with a dihydropyrimidine dehydrogenase deficiency; medication which might affect 
immunocompetence such as long term steroids or other immunosuppressants for an unrelated 
condition; men or women of reproductive potential, unless using at least two contraceptive 
precautions, one of which must be a condom.  
 
The primary endpoint was to investigate the efficacy of GV1001 on length of survival when 
added concurrently or sequentially to the combination gemcitabine and capecitabine.  The 
secondary endpoints were to evaluate the safety of GV1001 when added concurrently or 
sequentially to the combination gemcitabine and capecitabine; the efficacy measured as time 
to progression, objective response rate, quality of life, and changes in CA19-9 over time; 
immunogenicity measured as DTH and T-cell proliferation. The trial conformed to the 
principles of the International Conference on Harmonisation on Good Clinical Practice and 
was undertaken by the Cancer Research UK Liverpool Cancer Trials Unit; 
pharmacovigilance was sub-contracted to Orion Clinical Services Ltd (Slough, UK).  All 
participants provided written, informed consent before randomisation. 
 
Randomisation 
Treatments were allocated with equal probability by means of computer-generated random 
permuted blocks of sizes 3 and 6 in equal proportion, employing the Stata add-in ralloc. 
Randomisation was stratified on stage of disease (locally advanced versus metastatic) and 
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ECOG performance status (0, 1 and 2). The allocation sequence was generated by the then 
Trial Statistician and was held centrally with access restricted to the TeloVacTrial Senior 
Statistician, the Senior Trial Co-ordinator and the Data Managers. Patients were randomised 
by trained authorised staff within the Liverpool Cancer Trials Unit. 
Procedures 
Haematology and serum chemistry was undertaken at screening baseline then weekly for the 
first three consecutive weeks out of every four weeks until the end of study. Computed 
tomography scans were performed at baseline, then at eight, 20 and 32 weeks after the start of 
therapy and thereafter 12 weekly and assessed using RECIST criteria. Quality of life was 
assessed at baseline, eight weeks, and then every 12 weeks after the initial scan at eight weeks 
using the EORTC QLQ-C30 questionnaire.  
 
Patients randomised to control combination chemotherapy (arm1) received gemcitabine 
(1000mg/m
2
 30 minute intravenous infusion on days one, eight and 15) and capecitabine (830 
mg/m
2
orally twice daily of for 21 days) repeated every 28 days for six cycles or until disease 
progression, development of cumulative toxicities or patient choice.
22 
(Supplementary Figure 
S1). 
 
Patients randomised to sequential chemoimmunotherapy (arm 2) received two cycles 
ofcombination chemotherapy, and were then immunised by an intradermal injection of 
recombinant GM-CSF (75μg)  into the lower abdomen and 10-15 minutes later an 
intradermal injection at the same site of 0.56 mg (200l of 2·8 mg/ml) of GV1001.10 The 
GV1001 vaccine was manufactured by Elaiapharm SAS (2881 Route des Crêtes, BP 205 
Valbonne, 06904 Sophia Antipolis Cedex France). Immunisation was undertaken on days 
one, three, andfive during week one, then once on weeks two, three, four, andsix and then 
TeloVac Trial Lancet Oncology [Revised v2.1] 8
th
 May 2014 
Page 12 of 35 
 
monthly. The primary vaccination schedule was defined as the first 10 weeks of vaccination, 
18 weeks after the start of chemotherapy. If there was disease progression GV1001 was 
stopped and gemcitabine and capecitabinewas re-started.  
 
Patients randomised to concurrent chemoimmunotherapy(arm 3) received combination 
chemotherapy with GV1001 from day one of therapy. The primary vaccination schedule was 
similarly defined as the first 10 weeks of vaccination, but in this arm 10 weeks after the start 
of chemotherapy. 
Dose reduction by 75% on the day of gemcitabine administration was required if the absolute 
neutrophil count was reduced to 0.5-1.0 x10
9
/L and omitted for one week if <0.5x10
9
/L ;  
following an episode of febrile neutropaenia, all subsequent courses would be given at 75% 
dose. Dose reduction by 75% on the day of gemcitabine administration was also required if 
the absolute platelet count was reduced to 50-100x10
9
/L and omitted for one week if 
<50x10
9
/L. Dose modifications of capecitabine for non-haematological toxicities notably 
gastrointestinal disorders, especially diarrhoea, nausea, vomiting and stomatitis, and hand-
foot syndrome for grade 2 (NCI CTCAE) were to interrupt until resolved to grade 0-1 if first 
appearance and maintain dose level for the next cycle; if second appearance then interrupt 
and reduce to 75% with prophylaxis in the next cycle; and if third appearance interrupt and 
reduce 50% in the next cycle. Similarly for grade 3 toxicity for first and second appearances 
but discontinue treatment permanently if third appearance and also if grade 4. If patients 
experienced an episode of febrile neutropenia or had a neutrophil count of <0.5x10
9
/L or 
aplatelet count < 50 x10
9
/L, then capecitabine should be withheld and omitted until resolved 
to grade 0-1 toxicity. Patients should restart capecitabine at 75% dose.  
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DTH testing was undertaken in arms 2 and 3 by administering simultaneously a second 
intradermal injection of 0·105mg of GV1001 at the contra-lateral site on the lower abdomen 
without concomitant GM-CSF and read 48 hours later. DTH testing was continued until the 
result was positive or the vaccine therapy discontinued.  
 
T-cell proliferation wasassessed in a sub-set of patients. Thawed peripheral blood 
mononuclear cells (PBMCs) were seeded in 48 well plates (ThermoFisher Scientific, USA) at 
2x10
6
 cells/well in X-VIVO 15 (Lonza, UK) with 10% pooled human serum (Innovative 
Research, USA) and 20μg/ml GV1001 peptide. Following three days of culture, the media 
was changed to a final concentration of 10 units/ml of interleukin (IL)-2 (Peprotech, UK). On 
day 11, the GV1001-enriched cells were harvested and placed in a round bottom 96 well plate 
(50µl, 1x10
5
cells/well). To the pre-stimulated cells, irradiated (45Gy) autologous PBMCs 
(50µl, 1x 10
5
cells/well) were added to act as antigen presenting cells. GV1001-specific 
proliferation was tested for by the addition of 100µl of either control media, 20µg/ml 
GV1001, or positive control with 5µg/ml phytohaemagglutinin (PHA). After afurther 48 
hours incubation, 1µCi/well of 
3
H-thymidine was added for 16 hours before counting. A 
positive proliferative response to GV1001 was defined as a stimulation index above 1·8 with 
a significant difference in counts per minute from four replicates.  A positive total immune 
response was defined as a positive DTH test and/or a positive proliferation assay. 
 
Patients could withdraw because of patient’s decision to discontinue in the trial; disease 
progression according to RECIST; and intolerable adverse effects. Patients had to withdraw 
due to pregnancy; recurrent grade 3 or 4 drug related toxicity despite dose modification; 
serious systemic allergic reaction to any of the study drugs such as angio-oedema or 
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anaphylaxis; intercurrent, unrelated conditions requiring long term usage of steroids;  and 
should they miss two consecutive GV1001 administrations or three GV1001 non-consecutive 
administrations during the entire treatment course and/or two consecutive cycles of 
gemcitabine and capecitabine administrations  or three non-consecutive cycles during the 
entire treatment course. The National Cancer Institute Common Toxicity Criteria for Adverse 
Events versdion 3 was used to record toxicity 
Statistical Analysis 
1110 patients (780 deaths expected), were required to detect a 10%  improvement in one-year 
survival foreither experimental arm above the 25% survival expected in the standard arm.  A 
two-sided α of 0·025 (corresponding to a 97·5% confidence interval) was set for each 
primary response comparison of chemoimmunotherapy versus standard chemotherapy,with a 
total 0·05 level of significance andat least 80% power for the trial as a whole.  The sample 
size additionally adjusted for four formal interim and one final analysis on the primary 
endpoint (O’Brien–Fleming type boundaries based on the Lan-DeMetsα-spending function).  
For the third and subsequent interim analyses futility for the primary outcome was assessed 
by estimating conditional power.  In practice, as the trial terminated early, 98.25% intervals 
(significance of 0.0175) were applied to all analyses of the primary endpoint involving 
comparison between treatment arms. 
 
The full analysis set consisted of all randomised patients in order to follow the intention to 
treat principle excepting for patients withdrawing consent between randomisation and starting 
therapy and patients withdrawn from the study after randomisation because of irregularities 
with the consent process.  The per protocol set consisted of those patients in the full analysis 
set without any major protocol deviations.  For per-protocol analysis for the primary 
endpoint, deviations were reviewed by the chief investigator to categorise protocol deviations 
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that would affect the outcome.  The safety set comprised all patients who received any trial 
treatment. Sensitivity analysis included testing the proportional hazards assumption, 
additional stratification for CA19-9 levels, allowance for random centre effect and testing for 
treatment x centre interaction. For per-protocol analysis for the primary endpoint, deviations 
were reviewed by the chief investigator to categorise protocol deviations that would affect the 
outcome.   
The final statistical analysis was performed with Stata v12.1, based on intention-to treat.  
Overall survival and time to progression were estimated by the Kaplan-Meier method, with 
hazard ratios (HRs) and confidence intervals obtained from a stratified Cox model and p-
values from the corresponding stratified log-rank test (strata as defined for the 
randomisation).  For other pre-specified outcomes (including time to progression), for 
descriptive analyses involving only a single arm and for unplanned analyses a conventional 
95% two sided confidence interval was used with no correction.  
 
The trial was sponsored by the Royal Liverpool and Broadgreen University Hospitals NHS 
Trust, Liverpool, UK. The GM-SF and GV1001 vaccine were supplied by KAEL-GemVax 
Co.,Limited and the capecitabine was supplied by Roche. 
The Protocol may be viewed on the following link: 
https://www.lctu.org.uk/trial/trial_links.asp?id=42&tgcode=4&menuid=43 
 
Role of the Funding Sources and Sponsor 
Neither the sponsors nor funders had any role in the design and conduct of the study; the 
collection, management, analysis, and interpretation of the data; nor the preparation, review, 
or approval of the presentation. GM, PS, TC, WG, VS, EC, CR, GN and JN had access to the 
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raw data. The corresponding author had full access to all of the data and the final 
responsibility to submit for publication 
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RESULTS 
There were 1572 patients who  were screened to take part in the study with 402 excluded due 
to ineligibility and 108 declining to take part. The first patient was randomised on the 29
th
 
March 2007 and the trial was terminated slightly ahead of target on the 27
th
 May 2011, with 
1062 patients recruited, due to unfavourable survival fromsequential chemoimmunotherapy 
(CONSORT, Figure 1).  Baseline characteristics were well balanced across all three groups 
(Table 1). 
 
There were 741deaths, (95% of the 780 target number of deaths or 73% of the total). The 290 
patients still alive had been followed up for a median of 6·0 (inter-quartile range,2·4-12·2) 
months. The overall median survival was 7·60 (95% CI, 7•11-8•12) months with 12 and 24 
month survival rates of 30·43 (95% CI, 27·34-33·•56) % and 9·42 (95% CI, 7·23-11·96)% 
respectively.Baseline clinical stage, blood carbohydrate antigen (CA) 19-9 levels and ECOG 
performance status were all associated with survival (p< 0•001 for each factor on univariate 
analysis). After mutual adjustment, the respective hazard ratios (each compared against the 
lowest category of each variable) were: metastatic disease, 1·51 (95% CI: 1·27 – 1·79, 
P<0·001; ECOG level 1, 1·46 (95% CI: 1·23 - 1·73, P<0·001);   ECOG level 2, 3·08 (95% 
CI: 2·40 - 3·96, P<0·001); and for  CA199 2
nd
-4
th
 quartiles, 1·33 (95% CI: 1·07 - 1·65, 
P=0·009), 1·53 (95% CI: 1·24 - 1·89, P<0·001), 2·41 (95% CI: 1·95 - 2·97, P<0·001) (Table 
2; supplementary figures S2-S4). 
 
The median overall survival times for the chemotherapy arm (n=358), sequential 
chemoimmunotherapy arm (n=350) and the concurrent chemoimmunotherapy arm (n=354) 
were 7.89 (95% CI: 7.07- 8.85), 6.94 (95% CI 6.35-7.6) and 8.36 (95% CI: 7.30 -9.74) 
months respectively (Table 3 and Figure 2). The corresponding hazard ratios for the 
TeloVac Trial Lancet Oncology [Revised v2.1] 8
th
 May 2014 
Page 18 of 35 
 
chemoimmunotherapy arms were 1.19 (98.25% CI: 0.97-1.48, p=0.047) and 1.05 (98.25% 
CI: 0.85-1.29, p=0.64), with an overall log-rank of χ22df= 4.3; P=0•11).  Given the 
predetermined two-sided α of 0·025 this was not statistically significant. The 12 month 
survival rates were 33·7%, 25·3% and 32·3% respectively. The lack of treatment effect on 
survival was consistent between the stages (Global Likelihood-ratio test for Treatment x 
Stage interaction, χ22df= 1•36, P= 0•51).Compared to chemotherapy alone there was no 
survival benefit in patients with a lower tumour burden (locally advanced) and the best 
performance status (ECOG = 0) randomised to sequential chemoimmunotherapy (HR =1·20; 
95% CI 0·59-2·45)nor to concurrent chemoimmunotherapy (HR=0·85; 95% CI 0·41-1·76) 
(Figure 2).An unplanned post-hoc analysis showed that the overall survival of the 84 patients 
randomised to sequential chemoimmunotherapy who returned to standard chemotherapy 
following progression on vaccination therapy and alive at 18 weeks was not dissimilar to 
patients alive at 18 weeks randomised to standard chemotherapy (HR=0·84; 95% CI, 0·58-
1·23; p=0·28) (Supplementary figure S5). 
 
The possibility that treatment effects might differ according to tumour stage, ECOG 
performance status and CA19-9 level was assessed by a likelihood ratio test nesting a main-
effects only model within one including interactions (χ212df=13·76, P = 0·32). 
 
The median overalltimes to progression (TTP) for the chemotherapy, sequential 
chemoimmunotherapy and the concurrent chemoimmunotherapy arms were 6.35 (95% CI: 
4.77- 7.07), 4.54 (95% CI 4.34-4.61) and 6.58 (95% CI: 5.03 -7.27) months, with 
corresponding hazard ratios for the chemoimmunotherapy arms of 1.50 (98.25% CI: 1.26-
1.78, p<0.001) and 1.0 (98.25% CI: 0.84-1.19, p=0.99) with overall log-rank χ22df = 29·5; 
P<0•001) (Figure 3). 
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A partial or complete clinical response was observed at eight weeks in 90 (8·47%) patients 
(95% CI, 6·80-10·15%) with no significant difference across the three arms. An overall 
response was observed in 149 (14·03%)patients(95% CI,11·94-16·12), significantly worse 
for patients randomised to sequential chemoimmunotherapy (Supplementary Table). 
 
DTH waspositive in 19(12·3%) of 154 patients randomised to sequential immunotherapy 
(conditional on survival to 18 weeks) and in 47 (20·2%) of 233 patients randomised to 
concurrent chemoimmunotherapy(conditional on survival to 10 weeks) (P=0·0531). Patients 
on sequential immunotherapy with a positive DTH response had a median survival of 7·5 
(95% CI, 3·5-9·5) months and 5·8 (95% CI, 3·9-7·1) months with a negative response 
(HR=0·95; 95% CI, 0·49-1·84) (χ21df=0·036, P=0·85).  The median survival in patients 
onconcurrent chemoimmunotherapywith a positive DTH response was 9·0 (95% CI, 6·1-
10·9) months and 8·0 (95% CI, 6·6-8·7) months with a negative response(HR=0·98; 95% CI, 
0·60-1·59) (χ21df = 0·015, P=0·90) (Figure 4).  
 
T-cell proliferation waspositive in 10 (31·3%) of 32 patients given sequential immunotherapy 
and 10 (14·7%) of 68 patients givenconcurrent chemoimmunotherapy(P=0·065). There was a 
total immune response in 12 (37·5%) of32 patients on sequential immunotherapy and 
25(36·8%) of 68 patients onconcurrent chemoimmunotherapy (P=1•0); 12 (40%) of 30 and 
25 (39.6%) of 63 patients respectively without missing values (p=1•0).The median survival 
(from week 18) in patients on sequential immunotherapy arm witha positive total immune 
response was 8·4 (95% CI, 7·0-NA) months and 7·3 (95% CI, 3·0-29·2) months with a 
negative response (HR=0·28; 95% CI, 0·05-1·53)(χ21df=2·368, P=0·12). The median survival 
(from week 10) in patients randomised to concurrent chemoimmunotherapy was 10·6 (95% 
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CI, 6·2-13·7) months and 12·2 (95% CI, 7·2-16·6) months respectively (HR=1·57; 95% CI 
0·71-3·49) (χ21df =1·241, P = 0·27) (Supplementary figure S6). The pooled hazard ratio for 
positive total immune responsewas 1·15 (95%CI, 0·56-2·38) (χ21df =3·208, P=0·073). 
 
The standard chemotherapy regimen was well tolerated and there was no evidence of any 
additional toxicity from sequential or concurrent immunotherapy (Tables 4a nd 4b). The 
numbers of patients with dose modification as a result of toxicity in each arm are shown in 
table 4c. There were 32 (3%) patients altogether who withdrew because of toxicity, 15 (4%) 
patients from the standard chemotherapy arm, four (1%) from the sequential 
chemoimmunotherapy arm and 13 (4%) from the concurrent chemoimmunotherapy arm 
(χ22df=6.4; p=0.04). There were four (1%) deaths due to drug-related toxicity in the standard 
chemotherapy arm, five (1%)  in the sequential chemoimmunotherapy arm and six (2%)  in 
the concurrent chemoimmunotherapyy arm (P=0·811). Patients randomised to sequential 
immunotherapy had a significantly higher pain score compared to patients randomised to 
standard chemotherapy at 20 weeks (fitted mean difference 32·88; 95% CI, 17·49-48·26; 
P<0·001) and a lower QOL score (fitted mean difference -19·62; 95% CI, -34·90- -
4·34;P=0·012) (Table 5). 
 
The per protocol analysis was undertaken after removing 62 deviations (21, 21 and 20 in 
Arms 1, 2 and 3 respectively) that were identified as having the degree of seriousness 
deserving exclusion. The results of this analysis did not materially alter in any way the 
outcomes of the intention to treat analysis. 
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DISCUSSION 
The trial demonstrated that there was no survival benefit for the addition of the GV1001 
vaccine to gemcitabine and capecitabinein patients with advanced pancreatic cancer. A 
positive DTH, T-cell proliferation and total immune response was observed in 12.3%, 
31·3%and 37·5% respectively of patients given sequential chemoimmunotherapy and in 
20.2%, 14.7% and 36·8% respectively of patients given concurrent chemoimmunotherapy but 
there was no association with survival. The total immune response in the phase II study 
compared to that seen in the current study is consistent in the reduction in response rates 
generally observed in the transit from phase II to phase III studies.
10 
In order for a cancer 
vaccine to be effective an active immune response is needed and this is dependent on a 
sufficient period of time for this to develop. The characteristic early metastasising and rapidly 
progressive nature of pancreatic cancer may partly explain the lack of clinical efficacy but 
there are also other complex immunological and stromal factors that need to be overcome.
24-
26
The dense stromal reaction impedes the penetration of cytotoxics into pancreatic tumours 
thus limiting the synergistic potential of chemotherapy and GV1001 vaccination intended to 
achieve CD40 activation and generate telomerase-specific T helper cells.
25 
Direct CD40 
activation (using the agonist CP-870,893) with gemcitabine chemotherapy has recently been 
shown to cause a partial tumour response in four of 21 patients with advanced  pancreatic 
cancer but surprisingly this effect was due to stroma infiltrating macrophages rather than T 
cells.
26 
 
An effective active immune response may also be dependent on a lower tumour burden and 
good performance status but recent studies from other tumour typesdo not appear to support 
this. In a randomized phase II trial of prostate cancer involving PROSTVAC-VF (consisting 
of two prostate specific antigen [PSA] encoding viral vectors, and the B7.1, ICAM-1, and 
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LFA-3 co-stimulatory molecules) and GM-CSF there was  no survival improvement in men 
with fewer bony metastases  or an ECOG performance status of zero.
27
Similar findings were 
found in the IMPACT phase III trial in men treated with sipuleucel-T (Provenge) a form of 
active cellular immunotherapy(autologous PBMCs activated with the recombinantPA2024 
protein composed of a prostate antigen and prostatic acid phosphatase, fused to GM-CSF).
28
 
In the TeloVac trial there was also no impact on survival by either stage of disease or 
performance status from GV1001 vaccination. 
 
Identifying robust immunotherapy response signatures in human cancer studies remains 
challenging across tumour types.In the PROSTVAC-VF trial there was no antibody response 
to PSA and although all generated titres to one or both viralvectors there was no association 
with survival.
27
In the IMPACT trial, although there was a T-cell proliferation response to 
PA2024 in 46 (73·0%) of 63 patients given sipuleucel-T, only 15 (27·3%) of 55 patients had 
a T-cell response against the target antigen prostatic acid phosphatase. As in the TeloVac trial 
there was no association with survival although patients with a high antibody titre against 
PA2024 lived longer.
28
The limited immunotherapeutic responses seen in these studies as well 
as in TeloVac trial may partly be due to inhibitory T-cell checkpoints that minimise T-cell 
cytotoxicity.
5
 These include the cytotoxic T-lymphocyte associated antigen (CTLA)-4 
binding of ligands and at a later point programmed death (PD)-1 receptor 
activation.
5
Combined blockade of both these check points produced a tumour response in 21 
(40%) of 52 patients with advanced melanoma.
6
A randomised phase II study of 30 patients 
previously treated for advanced pancreatic cancer comparing the anti-CTLA-4 antibody 
ipilimumab alone with ipilimumab plus  a GM-CSF cell-based vaccine (GVAX) showed 
stable disease in two patients in each of the two arms with no objective responses although 
there was a trend towards increased median survival of  5.7versus  3.6 moths respectively.
29 
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In a trial of an anti-PD-L1 antibody (BMS-936559)  in 207 patients, objective responses were 
reported in malignant melanoma, renal-cell cancer, non-small cell lung cancer, and ovarian 
cancer but none in 14 patients with advanced pancreatic cancer.
30 
The relative lack of 
immunotherapy efficacy in pancreatic cancer may also in part be related to specific 
carcinoma-associated fibroblasts (expressing fibroblast activation protein) which secrete 
CXCL12 and thus stop T cells from accessing cancer cell regions in the stroma. In a 
genetically engineered mouse model of  pancreatic cancer blocking the receptor of CXCL12, 
induced rapid T-cell accumulation and synergised with α-PD-L1 in cancer cell killing.31 
 
There have been concerns raised about the use of GM-CSF as adjuvantbased on the induction 
of myeloid derived suppressor cells (MDSCs) by low-dose GM-CSF,
32
 but we have 
demonstrated that the levels of MDSCs  were reduced  in patients treated with GV1001, GM-
CSF and concomitant chemotherapy compared with chemotherapy alone.
33 
 
There was a shorter time to progression observed after the administration of two cycles of 
chemotherapy in the sequential chemoimmunotherapy arm. A post-hoc analysis showed that 
the overall survival in this group of patients who returned to standard chemotherapy 
following progression on vaccination  therapy was not different from comparable patients 
randomised to standard chemotherapy. These findings suggest that treatment until 
progression is the appropriate approach in pancreatic cancer and is consistent with the recent 
findings that a minimum of six cycles of chemotherapy is necessary for optimum survival 
benefit in the adjuvant setting.
34 
The TeloVac study has demonstrated the challenges for 
immunotherapy study design when immunotherapy is combined with standard therapy in the 
first line setting and highlights the uncertainties in extrapolating treatment scheduling from 
experimental models to the clinical setting. One option that had been considered was 
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vaccination after six cycles of chemotherapy rather than two cycles but it was important to 
test institution of vaccination after initial stabilization of disease before progression, and at a 
time when apoptosis was likely to be still high.  In this study the median progression free 
survival on chemotherapy alone was 6.3 months therefore 50% of patients would have 
progressed at this point. For future immunotherapy trials randomized phase II studies 
employing adaptive trial designs should be seriously considered to explore different 
scheduling regimens that do not compromise standard treatment. 
 
The TeloVac trial has demonstrated that vaccination to hTERT can elicit immune responses 
during chemotherapy but without clinical efficacy. There are presently a number of different 
approaches being used to target telomerase in cancer including small-molecule telomerase 
inhibitors which may be more effective in tumours with shorter telomeres.
35, 36 
There are 
opportunities now to uncloak the mechanism of action of vaccines such as GV1001 using 
multi-modality strategies that are directed against the stroma and check point inhibition as 
well as direct CD40 activation. 
 
PANEL: RESEARCH IN CONTEXT 
Systematic review 
In trial set up for the treatment of locally advanced and metastatic pancreatic two systematic 
reviews were undertaken.
37,38
 The search (Medline, OLDMEDLINE, CancerLit,EMBASE, 
and ISI Web of Science, ISI Science and Technology Proceedings, Current contents 
databases, trial registries and conference proceedings) involved randomized controlled trials 
involving patients with advanced pancreatic cancer of chemotherapy, novel agents, 
radiotherapy, chemoradiotherapy and best supportive care. PubMed was searched for any 
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clinical trial and experimental work for telomerase, immunotherapy, vaccines, cancer, 
pancreatic cancer, and GV1001.
39 
 
The reviews showed that chemoradiation followed by chemotherapy did not demonstrate any 
survival advantage over chemotherapy alone. There was a significant survival benefit for 
chemotherapy over best supportive care and gemcitabine combinations over gemcitabine 
alone including gemcitabine with capecitabine. The evidence did not support the use of 
GV1001 vaccine alone but should be tested along with chemotherapy. The combination of 
gemcitabine with capecitabine was chosen as this could potentiate the vaccine effects and 
was also associated with significantly improved objective responses compared to gemcitabine 
alone.
22,37,38 
Interpretation 
This is one of the largest randomized clinical trials ever undertaken in pancreatic cancer and 
the largest trial of vaccine therapy ever undertaken in any solid cancer type. There was no 
survival benefit from the addition of the GV1001 vaccine to gemcitabine and capecitabine in 
patients with advanced pancreatic cancer. Survival was not affected by immune response, 
stage of disease or performance status in patients given GV1001 vaccination. 
 
The TeloVac trial demonstrated immune responses in patients being given a cancer vaccine 
with concurrent chemotherapy in a broadly similar proportion of patients receiving vaccine 
therapy alone in pancreatic and prostate cancer and also malignant melanoma. The TeloVac 
trial demonstrated progression of disease once the initial two cycles of chemotherapy was 
stopped, in the sequential chemoimmunotherapy arm, suggesting that treatment, including 
chemotherapy should continue until progression. 
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During the course of the trial there has been a major development in clinically relevant 
genetically engineered models that has significantly contributed to the deeper understanding 
of the biological mechanisms that undermine the effective treatment of pancreatic 
cancer.
25,26,31
 These can now be countered and could be deployed in multimodality strategies 
to overcome the key biological constraints to effective treatment.  
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LEGENDS 
 
Figure 1. CONSORT diagram  
Figure 2.Overall survival by treatment arm and hazard ratios of sequential 
chemoimmunotherapy (arm 2) versus standard chemotherapy (arm 1) and concurrent 
chemoimmunotherapy (arm 3) versus standard chemotherapy (arm 1) by ECOG performance 
status and stage. 
 
Figure 3.Time to progression by treatment arm. 
 
Figure 4.Overall survival according to a positive or negative DTH response in patients 
randomised to sequential chemoimmunotherapy (arm 2) conditional on reaching week 18 (A) 
and in patients randomised to concurrent chemoimmunotherapy (arm 3) conditional on 
reaching week 10 (B). 
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